TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05815576

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intrinsic foot muscle fatigue
Description: Electrostimulation will be delivered through electrodes placed on the abductor hallucis (NOT invasive).~The investigators plan 4 sets of 4 minutes of repeated contractions (electrostimulation + voluntary contraction).
Study: NCT05826899

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 54Fe SO4
Description: 4 mg of iron as FeSO4 labelled with 4 mg of 54Fe

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 54Fe SO4
Description: 4 mg of iron as FeSO4 labelled with 4 mg of 54Fe

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 54Fe SO4
Description: 4 mg of iron as FeSO4 labelled with 4 mg of 54Fe

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 54Fe SO4
Description: 4 mg of iron as FeSO4 labelled with 4 mg of 54Fe

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 54Fe SO4
Description: 4 mg of iron as FeSO4 labelled with 4 mg of 54Fe

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 54Fe SO4
Description: 4 mg of iron as FeSO4 labelled with 4 mg of 54Fe

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 57Fe Oat-1
Description: 4 mg of iron as 0.46 g Fe-oat 1 (Oat fibrils, ascorbic acid reduced) labelled with 57Fe

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 57Fe Oat-1
Description: 4 mg of iron as 0.46 g Fe-oat 1 (Oat fibrils, ascorbic acid reduced) labelled with 57Fe

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 57Fe Oat-1
Description: 4 mg of iron as 0.46 g Fe-oat 1 (Oat fibrils, ascorbic acid reduced) labelled with 57Fe

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 57Fe Oat-1
Description: 4 mg of iron as 0.46 g Fe-oat 1 (Oat fibrils, ascorbic acid reduced) labelled with 57Fe

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 57Fe Oat-1
Description: 4 mg of iron as 0.46 g Fe-oat 1 (Oat fibrils, ascorbic acid reduced) labelled with 57Fe

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 57Fe Oat-1
Description: 4 mg of iron as 0.46 g Fe-oat 1 (Oat fibrils, ascorbic acid reduced) labelled with 57Fe
Study: NCT05578807

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: without reverse ureteral catheter insertion
Description: In contrast to conventional total tubeless percutaneous nephrolithotomy, there was no reverse insertion of a ureteral catheter by transurethral ureteroscopy when a patient is placed in lithotomy position, no change in position, and no repeated disinfection.
Study: NCT05691400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib 125Mg Tab
Description: 125 mg single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib 125Mg Tab
Description: 125 mg single dose
Study: NCT05498116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast
Description: 10mg daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 capsule daily
Study: NCT06253624

Intervention type: PROCEDURE
Group type: OTHER
Intervention: All Arthroscopic ATFL Repair Surgery
Description: The patients undergo surgery with spinal block, general anesthesia, or a combination of both. During the diagnostic arthroscopy, the anterior compartment is examined with a 4 mm 30-degree camera, and lateral ankle instability is diagnosed arthroscopically
Study: NCT05257369

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blue-Green LED photoherapy
Description: Continuous phototherapy for 24 h, for newborns placed incubators or radiant warmers will interrupted only for feeding and nursing for 20 - 30 min every three hours.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Blue-Green LED photoherapy
Description: Continuous phototherapy for 24 h, for newborns placed incubators or radiant warmers will interrupted only for feeding and nursing for 20 - 30 min every three hours.
Study: NCT05826899

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 58Fe Oat-2
Description: 4 mg of iron as 0.46 g Fe-Oat 2 (Fe-Oat with NaOH) labelled with 58Fe.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 58Fe Oat-2
Description: 4 mg of iron as 0.46 g Fe-Oat 2 (Fe-Oat with NaOH) labelled with 58Fe.
Study: NCT05691400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib 125Mg Tab
Description: 125 mg single dose
Study: NCT05826899

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 58Fe Oat-2
Description: 4 mg of iron as 0.46 g Fe-Oat 2 (Fe-Oat with NaOH) labelled with 58Fe.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 58Fe Oat-2
Description: 4 mg of iron as 0.46 g Fe-Oat 2 (Fe-Oat with NaOH) labelled with 58Fe.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 58Fe Oat-2
Description: 4 mg of iron as 0.46 g Fe-Oat 2 (Fe-Oat with NaOH) labelled with 58Fe.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 58Fe Oat-2
Description: 4 mg of iron as 0.46 g Fe-Oat 2 (Fe-Oat with NaOH) labelled with 58Fe.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 54 FeSO4 + Acai puree with honey
Description: 4 mg of iron as FeSO4 labelled with 4 mg of 54Fe given with 30 mL acai puree with honey.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 54 FeSO4 + Acai puree with honey
Description: 4 mg of iron as FeSO4 labelled with 4 mg of 54Fe given with 30 mL acai puree with honey.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 54 FeSO4 + Acai puree with honey
Description: 4 mg of iron as FeSO4 labelled with 4 mg of 54Fe given with 30 mL acai puree with honey.
Study: NCT05691400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib 200Mg Oral Tablet
Description: 200 mg single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib 200Mg Oral Tablet
Description: 200 mg single dose
Study: NCT05826899

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 54 FeSO4 + Acai puree with honey
Description: 4 mg of iron as FeSO4 labelled with 4 mg of 54Fe given with 30 mL acai puree with honey.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 54 FeSO4 + Acai puree with honey
Description: 4 mg of iron as FeSO4 labelled with 4 mg of 54Fe given with 30 mL acai puree with honey.
Study: NCT05691400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib 200Mg Oral Tablet
Description: 200 mg single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib 150 MG Oral Tablet
Description: 150 mg single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib 150 MG Oral Tablet
Description: 150 mg single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib 150 MG Oral Tablet
Description: 150 mg single dose
Study: NCT06230588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQH3906 capsule
Description: TQH3906 is a kinase inhibitor.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TQH3906 placebo
Description: Placebo Comparator
Study: NCT05815017

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Yoomi Physical Therapy Software
Description: Physical Therapy software via a computer/monitor will be set up for the patient. It will begin with a tutorial video for different exercises in the form of games and then ask patients to perform in sequence with prompting and motion tracking. Exercises include Frontal Bicep Curls, Arm Crosses, Press Ups, Arm Rotations, and Basketball Shots.
Study: NCT05131828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin and clemastine in combination
Description: Metformin hydrochloride 500 mg prolonged release (SR) tablet for oral administration.~Clemastine hydrogen fumarate 1.34 mg tablet for oral administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets to match both metformin and clemastine tablets.
Study: NCT06198166

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cuevas Medek
Description: Group A: will receive Cuevas Medek (CME) In a following procedure: supporting the patient in balance at the leg level and with slight posterior support. Then, once kept in the air for few seconds, slight up and down oscillations will make. The materials that will be used consists of three wooden boxes with the same dimensions (20cm x 40cm x 60cm), a bigger box, a wooden plate and two planks with the same dimensions (17cm x 80cm). Boxes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard kinetic programs
Description: Group B: will receive standard kinetic programs consisting of stretching (2 sets 15 repetitions with 5 seconds hold) , passive mobilizations (2 sets of 20 repetitions), orthosis( for 6 hours). These techniques and orthotics devices typically focus on tight muscles, maintain proper foot alignment and to address sensory processing difficulties and promote relaxation. Stretching will focus on the hamstrings and calf muscles tightness.
Study: NCT05826899

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 54 FeSO4 + Acai puree with honey
Description: 4 mg of iron as FeSO4 labelled with 4 mg of 54Fe given with 30 mL acai puree with honey.
Study: NCT05125965

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: additional time for the MRI
Description: 3 additional minutes to perform the MRI
Study: NCT05223140

Intervention type: BEHAVIORAL
Intervention: Birth within 7 minutes of rumping
Description: Birth within 7 minutes of rumping (+3 station), within 5 minutes of birth of pelvis, within 3 minutes of birth of umbilicus

Intervention type: BEHAVIORAL
Intervention: Birth within 7 minutes of rumping
Description: Birth within 7 minutes of rumping (+3 station), within 5 minutes of birth of pelvis, within 3 minutes of birth of umbilicus

Intervention type: BEHAVIORAL
Intervention: Premature cord clamping
Description: Umbilical cord clamping \<1 minute following birth

Intervention type: BEHAVIORAL
Intervention: Premature cord clamping
Description: Umbilical cord clamping \<1 minute following birth
Study: NCT05531110

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cataract surgery with insertion of Eyhance ICB00
Description: Cataract surgery with insertion of Eyhance ICB00
Study: NCT04856098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol maleate and glycopyrronium bromide
Description: Batch A Ultibro Breezhaler 85/43 μg 2 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol maleate and glycopyrronium bromide
Description: Batch A Ultibro Breezhaler 85/43 μg 2 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol maleate and glycopyrronium bromide
Description: Batch A Ultibro Breezhaler 85/43 μg 2 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol maleate and glycopyrronium bromide
Description: Batch A Ultibro Breezhaler 85/43 μg 1 capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol maleate and glycopyrronium bromide
Description: Batch B Ultibro Breezhaler 85/43 μg 2 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ultibro Breezhaler with oral charcoal
Description: Activated charcoal suspension, granules 50 g / bottle
Study: NCT05826899

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 57Fe Oat-1 + Acai puree with honey
Description: 4 mg of iron as 0.46 g Fe-oat 1 (Oat fibrils, ascorbic acid reduced) labelled with 57Fe given with 30 mL acai puree with honey.
Study: NCT05531110

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cataract surgery with insertion of Alcon SN60WF
Description: Cataract surgery with insertion of Alcon SN60WF
Study: NCT05884502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: combination of high-dose rosuvastatin and ezetimibe
Description: combination of rosuvastatin 20mg and ezetimibe 10mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: high-dose rosuvastatin single administration
Description: rosuvastatin 20mg monotherapy
Study: NCT06454097

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Assess the response glioma to radiochemotherapy using radiogenomics-based AI model
Description: Predict the radiochemotherapy sensitivity of patients with glioma using an established radiogenomics-based artificial intellegent mode
Study: NCT05717465

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anatomy diagrams
Description: The visual aids used included:~* An anatomical diagram illustrating how a lumbar puncture is carried out~* Paling palette, diagram illustrating the number of individuals affected by a particular condition~* Paling perspective scale, diagram comparing the risk of an event occurring in comparison to other 'everyday' risks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard informed consent
Description: Audio narration of a video containing text information relating to the lumbar puncture procedure (including risks) and an image of a consent form

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard informed consent
Description: Audio narration of a video containing text information relating to the lumbar puncture procedure (including risks) and an image of a consent form
Study: NCT05826899

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 57Fe Oat-1 + Acai puree with honey
Description: 4 mg of iron as 0.46 g Fe-oat 1 (Oat fibrils, ascorbic acid reduced) labelled with 57Fe given with 30 mL acai puree with honey.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 57Fe Oat-1 + Acai puree with honey
Description: 4 mg of iron as 0.46 g Fe-oat 1 (Oat fibrils, ascorbic acid reduced) labelled with 57Fe given with 30 mL acai puree with honey.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 57Fe Oat-1 + Acai puree with honey
Description: 4 mg of iron as 0.46 g Fe-oat 1 (Oat fibrils, ascorbic acid reduced) labelled with 57Fe given with 30 mL acai puree with honey.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 57Fe Oat-1 + Acai puree with honey
Description: 4 mg of iron as 0.46 g Fe-oat 1 (Oat fibrils, ascorbic acid reduced) labelled with 57Fe given with 30 mL acai puree with honey.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 57Fe Oat-1 + Acai puree with honey
Description: 4 mg of iron as 0.46 g Fe-oat 1 (Oat fibrils, ascorbic acid reduced) labelled with 57Fe given with 30 mL acai puree with honey.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 58Fe Oat-2 + Acai puree with honey
Description: 4 mg of iron as 0.46 g Fe-Oat 2 (Fe-Oat with NaOH) labelled with 58Fe given with 30 mL acai puree with honey

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 58Fe Oat-2 + Acai puree with honey
Description: 4 mg of iron as 0.46 g Fe-Oat 2 (Fe-Oat with NaOH) labelled with 58Fe given with 30 mL acai puree with honey

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 58Fe Oat-2 + Acai puree with honey
Description: 4 mg of iron as 0.46 g Fe-Oat 2 (Fe-Oat with NaOH) labelled with 58Fe given with 30 mL acai puree with honey

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 58Fe Oat-2 + Acai puree with honey
Description: 4 mg of iron as 0.46 g Fe-Oat 2 (Fe-Oat with NaOH) labelled with 58Fe given with 30 mL acai puree with honey

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 58Fe Oat-2 + Acai puree with honey
Description: 4 mg of iron as 0.46 g Fe-Oat 2 (Fe-Oat with NaOH) labelled with 58Fe given with 30 mL acai puree with honey

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 58Fe Oat-2 + Acai puree with honey
Description: 4 mg of iron as 0.46 g Fe-Oat 2 (Fe-Oat with NaOH) labelled with 58Fe given with 30 mL acai puree with honey
Study: NCT05851859

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiac coherence
Description: Use of Cardiac coherence (complementary respiratory training) during 6 month
Study: NCT05610423

Intervention type: OTHER
Intervention: no intervention
Description: No intervention. Observational study only
Study: NCT05038111

Intervention type: DRUG
Intervention: Dexmedetomidine
Description: perioperative dexmedetomidine infusion
Study: NCT05293821

Intervention type: DIAGNOSTIC_TEST
Intervention: TriQuik IVD
Description: TriQuik Invitro Diagnostic Device Cassettes. TriQuik Invitro Diagnostic Device Cassettes.

Intervention type: DIAGNOSTIC_TEST
Intervention: TriQuik IVD
Description: TriQuik Invitro Diagnostic Device Cassettes. TriQuik Invitro Diagnostic Device Cassettes.
Study: NCT06340490

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RJMty19 (CD19-CAR-DNT cells)
Description: Lentiviral vector-transducted double negative T cells (DNT) to express anti-CD19 CAR. Prior to cellular infusion, each patient received cyclophosphamide and fludarabine lymphodepleting chemotherapy.
Study: NCT06542991

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: transcranial magnetic stimulation
Description: During treatment, the patient underwent cTBS targeting the left SMA for 7 consecutive days. Each treatment day comprised six rounds of cTBS, with a 15-minute interval between each. A single cTBS session involved trains of three pulses at 50 Hz, repeated every 200 ms (5 Hz), until reaching a total of 600 pulses, lasting 40s. Stimulation intensity remained at 80% of resting motor threshold. In total, patients received 25,200 pulses throughout the treatment period.
Study: NCT05464459

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Novel elbow procedure
Description: A general anaesthetic plus upper limb nerve block is used with no tourniquet. Antibiotics and tranexamic acid are administered intravenously prior to procedure. Skin prepared by standard technique with alcoholic chlorhexidine. A posterior midline incision is made and lateral paraolecranon approach made to the elbow joint. Lateral ligament complex released for access and repaired at the end of the procedure. A 5mm high speed burr and HAPY burr instrument prepares the distal humerus. The trochlea spool and/or capitellum are resected to receive Pyrocarbon spherical prosthesis, size determined from pre-operative planning. The greater sigmoid notch is prepared in a similar manner with burr. A trial prosthesis is used to assess joint movement/stability before the Pyrocarbon spherical spacer inserted. Wound closed in layers with heavy vicryl. Skin closure with subcutaneous monocryl. Physiotherapist advice within 24 hours and immediate active mobilisation is commenced as comfort allows.
Study: NCT04435015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camostat Mesylate
Description: Participants will be given Camostat mesylate three times daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Microcrystalline Cellulose, NF
Description: Participants will be given Microcrystalline Cellulose (placebo) three times daily.
Study: NCT06390345

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FOCuSEd Integrated Intervention
Description: Participants randomized to the intervention will receive an integrated telehealth-delivered, remote lifestyle intervention that promotes healthy eating and 150 minutes per week of moderate-intensity physical exercise. This intervention will include a core curriculum during the first 3 months that includes: 1) a 12-session video based program; 2) goal setting and self-monitoring using a Fitbit tracker and MyFitnessPal; 3) lifestyle coaching; and 4) three tele-pulmonary rehab sessions and an additional 60-75 minutes of gradually increasing self-directed exercise per week. At the end of 3 months, we will offer to enter a recommendation for weight loss medications to intervention participants with a BMI of ≥ 27 kg/m2. In the post-core period (months 4-12), participants will continue to have as-needed access to the lifestyle coach.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: Participants in the enhanced usual care group will be referred to MOVE! (VA's weight loss management program) and pulmonary rehabilitation in coordination with their primary care provider.
Study: NCT06165978

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-monitoring
Description: pedometer/activity band provided to each participant

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Goal setting and review
Description: Goal setting and review (weekly: +15% of the previous week's average daily steps or walking time, or +1000 steps/day or +10 minutes walking - to be specified)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Educational sessions (face-to-face: providing a manual/explanatory brochure of the intervention; remote: addressing symptom pathophysiology, symptom management, among other topics)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feedback
Description: Daily or weekly feedback for patients (emotional/social support)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contact
Description: Contact with patients (face-to-face: for assessments; on remote: 1 -messages: for therapists' daily/weekly feedback or patient reports; 2 - calls: to adjust weekly goals or address doubts or issues)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercise based on patient preference, explaining how to identify moderate intensity (HRmax=64-76%, Borg 3-6) or vigorous intensity (HRmax=77-95%; Borg 7-8) and monitoring safety parameters (StO2\>88%, HRmax\<96%, Borg\<9)
Study: NCT06523062

Intervention type: DEVICE
Group type: OTHER
Intervention: blood pressure measurement
Description: automated blood pressure measurement on 3 occasions at each consultation, twice with one month apart
Study: NCT06280885

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants will be randomised to either the FIERCE exercise programme involving supervised exercise prescription

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Behaviour Change (Pedometer)
Description: Participants in both arms will be provided with a pedometer as a health behaviour change intervention
Study: NCT05982054

Intervention type: PROCEDURE
Group type: OTHER
Intervention: core decompression with local bone marrow mononuclear cells injection
Description: under local anesthesia ,anterior approach, with ultrasound and fluoroscopy guide
Study: NCT05488691

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EMDR
Description: The first session consists of recording the patient's history. In the second session the therapist evaluates the presence of coping mechanisms of the patient and, if necessary, suggests extra coping techniques. The following sessions are devoted to the reprocessing process. During these sessions, a target memory is identified and processed using EMDR. After a total of 8-10 sessions, it is expected that the patient will have achieved physiological reconciliation, relieved distress, and the ability to reformulate negative beliefs.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TAU
Description: treatment as usual for substance use disorders

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TAU
Description: treatment as usual for substance use disorders